Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Hypercalcemia Treatment Market – Insights
Hypercalcemia is characterized by increased level of calcium in the blood. The condition can be life-threatening and is associated with neoplastic diseases. Hypocalcemic drugs are used for the treatment of hypercalcemia.
The global hypercalcemia treatment market is estimated to account for US$ 10,696.6 Mn in terms of value in 2018 and is expected to reach US$ 28,060.0 Mn by the end of 2028.
Global Hypercalcemia Treatment Market: Drivers
High incidence of hypercalcemia is a major factor boosting growth of the global hypercalcemia treatment market. For instance, in the study, ‘Incidence of hypocalcemia and hypercalcemia in hospitalized patients: Is it changing?’, published in the Journal of Clinical and Translational Endocrinology, in September 2018, researchers found that 27.72% of the study patients suffered from hypocalcemia and 4.74% from hypercalcemia. Moreover, 585 cases of hypercalcemia were detected.
Moreover, increasing prevalence of cancer is also expected to aid in growth of the market. For instance, according to the World Health Organization, around 18.1 million new cases and 9.6 million deaths were registered due to cancer worldwide in 2018.
Moreover, favorable reimbursement scenario is also expected to aid in growth of the market. Reimbursements enable lesser out-of-pocket costs of treatment for patients, despite having a low income eligibility. For instance, Amgen has a reimbursement policy on its XGEVA (denosumab injection), in which the company pays the out-of-pocket amount in excess of US$ 25 per dose; up to US$ 10,000 in assistance per calendar year. Approximately 70% of XGEVA patients with commercial or Medicare coverage incurred US$ 0 out-of-pocket cost due to favorable reimbursement policy offered by Amgen, Inc.
North America region held dominant position in the global hypercalcemia treatment market in 2018, accounting for 45.5% share in terms of value, followed by Europe.
Global Hypercalcemia Treatment Market: Restraints
Companies face challenges with regard to locating patients for clinical trials and logistics issues related to institutes conducting trials. Such factors increase the costs incurred in R&D of hypercalcemia treatment, which is expected to hinder growth of the global hypercalcemia treatment market.
Moreover, it is challenging to distinguishing primary hyperparathyroidism from conditions that will not respond to parathyroidectomy, which is also expected to limit growth of the market.
Global Hypercalcemia Treatment Market: Opportunities
Product innovations in hypercalcemia drug types other than bisphosphonates is expected to offer lucrative growth opportunities for players in the global hypercalcemia treatment market. Bisphosphonate is the single largest product being utilized for hypercalcemia treatment. End users have recognized the bisphosphonate therapy as effective. Still, the global hypercalcemia treatment market is yet to witness major product innovations in the product types of calcitonin, calcimimetics, and glucocorticoids.
Improving systems for recognizing hypercalcemia can aid in addressing common causes for delayed diagnosis and treatment of the disease, thereby aiding in growth of the market. Educating patients and providers about the consequences of untreated disease can also help in this regard.
Bisphosphonates segment in the global hypercalcemia treatment market was valued at US$ 7,306.2 Mn in 2018 and is expected to reach US$ 19,798.3 Mn by 2027 at a CAGR of 11.7% during the forecast period.
Market Trends/Key Takeaways
R&D in the treatment of hypercalcemia is augmenting growth of the market. For instance, in July 2019, researchers from Ascendis Pharma A/S, in their study, ‘Design and Preclinical Development of TransCon PTH, an Investigational Sustained?Release PTH Replacement Therapy for Hypoparathyroidism,’ reported that TransCon PTH can be used to normalize blood levels of calcium and phosphate.
Sarcoidosis, a complex disease with no known cause, is linked with hypercalcemia. The study, “Hypercalcemic pancreatitis a rare presentation of sarcoidosis: A case report,” published in the journal Medicine in January 2018, reported a sarcoidosis patient with pancreatitis — inflammation of the pancreas — and hypercalcemia.
Global Hypercalcemia Treatment Market: Competitive Landscape
Major players operating in the global hypercalcemia treatment market include, Bayer Pharma AG, Sun Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Amgen Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Cipla Inc., and XOMA Corporation.
Global Hypercalcemia Treatment Market: Key Developments
Players in the market are focused on attending various conferences to expand their customer base. For instance, in October 2019, XOMA Corporation presented at the 2019 Cantor Fitzgerald Global Healthcare Conference held in New York.